These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7592829)

  • 1. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5.
    Hu DD; Lin EC; Kovach NL; Hoyer JR; Smith JW
    J Biol Chem; 1995 Nov; 270(44):26232-8. PubMed ID: 7592829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin alpha v beta 3.
    Hu DD; Hoyer JR; Smith JW
    J Biol Chem; 1995 Apr; 270(17):9917-25. PubMed ID: 7537271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins.
    Katagiri YU; Murakami M; Mori K; Iizuka J; Hara T; Tanaka K; Jia WY; Chambers AF; Uede T
    J Cell Biochem; 1996 Jul; 62(1):123-31. PubMed ID: 8836881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin.
    Bayless KJ; Davis GE
    J Biol Chem; 2001 Apr; 276(16):13483-9. PubMed ID: 11278897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
    Xuan JW; Hota C; Shigeyama Y; D'Errico JA; Somerman MJ; Chambers AF
    J Cell Biochem; 1995 Apr; 57(4):680-90. PubMed ID: 7542253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.
    Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A
    Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual control by divalent cations and mitogenic cytokines of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity expressed by human hemopoietic cells.
    Takamatsu Y; Simmons PJ; Lévesque JP
    Cell Adhes Commun; 1998 Jul; 5(5):349-66. PubMed ID: 9789683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
    Senger DR; Perruzzi CA; Papadopoulos-Sergiou A; Van de Water L
    Mol Biol Cell; 1994 May; 5(5):565-74. PubMed ID: 7522656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integrin specificity of human recombinant osteopontin.
    Caltabiano S; Hum WT; Attwell GJ; Gralnick DN; Budman LJ; Cannistraci AM; Bex FJ
    Biochem Pharmacol; 1999 Nov; 58(10):1567-78. PubMed ID: 10535747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalent cations regulate the organization of integrins alpha v beta 3 and alpha v beta 5 on the cell surface.
    Stuiver I; Ruggeri Z; Smith JW
    J Cell Physiol; 1996 Sep; 168(3):521-31. PubMed ID: 8816906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity.
    Hruska KA; Rolnick F; Huskey M; Alvarez U; Cheresh D
    Endocrinology; 1995 Jul; 136(7):2984-92. PubMed ID: 7540546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion.
    Xuan JW; Hota C; Chambers AF
    J Cell Biochem; 1994 Feb; 54(2):247-55. PubMed ID: 8175899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin.
    Yokosaki Y; Matsuura N; Sasaki T; Murakami I; Schneider H; Higashiyama S; Saitoh Y; Yamakido M; Taooka Y; Sheppard D
    J Biol Chem; 1999 Dec; 274(51):36328-34. PubMed ID: 10593924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the alpha4beta1 integrin-osteopontin interaction.
    Barry ST; Ludbrook SB; Murrison E; Horgan CM
    Exp Cell Res; 2000 Aug; 258(2):342-51. PubMed ID: 10896785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit.
    Chellaiah M; Fitzgerald C; Filardo EJ; Cheresh DA; Hruska KA
    Endocrinology; 1996 Jun; 137(6):2432-40. PubMed ID: 8641196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin adhesion receptors on gingival fibroblasts.
    D'Errico JA; Sauk JJ; Prince CW; Somerman MJ
    J Periodontal Res; 1995 Jan; 30(1):34-41. PubMed ID: 7536842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL; Chambers AF
    J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin.
    Schnapp LM; Hatch N; Ramos DM; Klimanskaya IV; Sheppard D; Pytela R
    J Biol Chem; 1995 Sep; 270(39):23196-202. PubMed ID: 7559467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis.
    Denda S; Reichardt LF; Müller U
    Mol Biol Cell; 1998 Jun; 9(6):1425-35. PubMed ID: 9614184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.
    Furger KA; Allan AL; Wilson SM; Hota C; Vantyghem SA; Postenka CO; Al-Katib W; Chambers AF; Tuck AB
    Mol Cancer Res; 2003 Sep; 1(11):810-9. PubMed ID: 14517343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.